We use cookies to personalize content, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. For information on how to change your cookie settings, please see our Privacy policy. Otherwise, if you agree to our use of cookies, please continue to use our website.

Blog

Highlighted Picks

Amazon Prime Day 2018: Trends, Notes, and Learnings from Another Record-Breaking Event

Examining Amazon ads performance for Merkle advertisers, several trends emerged to take note of.

Read Blog Post

Is Google Cloud Right For You?

It’s the number-one goal of any company: creating experiences across channels to maximize the acquisition of new and the retention of existing customers.

Read Blog Post

Latest Posts

Talking Personalization, Part 2

In our last post we focused on organizational readiness to delivering personalized experiences. Many organizations are realizing that personalization should be a strategy and not simply a marketing tactic.

Why Creative is Essential in Personalization

We all know great creative when we see it; the power of cultural meaning through a universal truth that is also personally relevant. I love that moment, the “aha” — when a brand’s proposition and its story are in sync. Those moments are few and far between today, with the vast majority of advertising considered boring, non-engaging, and even worse — irrelevant.

How to Segment and Target HCPs by Phase

In recent years, marketers have shifted their health care professional (HCP) marketing strategy from a "market aggregation" approach, which essentially treats everyone the same way, to a more targeted approach.
Topic: Health

Talking Personalization

People interpret personalization in various ways. At Merkle, we think about personalization as an ongoing exchange, not just a one-time project.

Beyond Price Wars: Using Copay Programs to Drive Adoption

The use of co-pay or coupon cards are typically considered for prescription drugs farther along in their lifecycle, when there are either new entrants in the category or when generics of less-expensive biosimilar products become available. A logical thought in the latter case is “all else being equal, a patient and prescriber will prefer the branded product.”
Topic: Health

What Does the Future Hold for Peer Reviewed Medicine?

Would you prescribe a drug just because other doctors “like” it? There are indications that this may already be happening, and health marketers should start thinking about what that means for them.
Topic: Health